Concert Pharmaceuticals Inc. (CNCE) 9.12 $CNCE
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59jtq3/chronic_kidney) has announced the addition of the "Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Concert Pharmaceuticals, Inc. - CorMedix, Inc. - Vitae Pharmaceuticals, Inc. - Stelic Institute & Co. - Sorbent Therapeutics, Inc. - Vicore Pharma AB - InVasc Therapeutics, Inc. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Chiasma, Inc. Drug Profiles - beraprost sodium LA - sotatercept - eculizumab - GCS-100 - deferiprone - (losartan potassium alpha lipoic acid) - tenapanor - LY-3016859 - enalapril maleate - SAR-407899 - VTP-27999 - CLP-1004 - CTP-499 - Ghrelin - THR-123 - C-21 - CAT-4000 Series - ANG-3070 - MultiGeneGraft - CXA-10 - CAT-4001 - SphK2 Program - TPX-200 - NZ-419 - Small Molecule to Inhibit Epoxide Hydrolase for Chronic Kidney Disease - Vida-5 - siRNA for Chronic Diseases - STNM-310 - ANG-4011 - Drug For Kidney Diseases - Chronic Kidney Disease Program - Drugs to Inhibit CYP24 for CKD and Pre-CKD - Small Molecules for Chronic Kidney Disease - Fluorophosphophloretin - BRN-1889 For more information visit http://www.researchandmarkets.com/research/59...nic_kidney
Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499 in Diabetic Kidney Disease
Business Wire - Fri Apr 25, 1:00PM CDT
--- CTP-499 reduced biomarkers of fibrosis -
Concert Pharmaceuticals, Inc. [CNCE] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Apr 11, 9:00AM CDT
What:
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.
Concert Pharmaceuticals Announces Filing of its Annual Report on Form 10-K
Business Wire - Mon Mar 31, 6:15AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.
Concert Pharmaceuticals Reports Year End 2013 Financial Results
Business Wire - Mon Mar 31, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.
Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting
Business Wire - Wed Mar 19, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that 48 week Phase 2 clinical results of CTP-499 in patients with diabetic kidney disease will be presented at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV. The podium presentation will be made by the lead author, Dr. Bhupinder Singh, a clinical investigator for the study at Southwest Clinical Research Institute, to present the clinical results during the Late Breaking Session on Friday, April 25, 2014, 9:30 am - 11:00 am PDT. A corresponding poster presentation will also be presented at the meeting and will include data describing the effect of CTP-499 treatment on several biomarkers of fibrosis. A copy of the corresponding abstract is available on the National Kidney Foundation's website at: http://www.kidney.org/news/meetings/clinical/.../index.cfm.
Concert Pharmaceuticals elects Dr Wendell Wierenga to board
M2 - Mon Mar 17, 5:05AM CDT
Biopharmaceutical company Concert Pharmaceuticals (NasdaqGM:CNCE) revealed on Friday the addition of Dr Wendell Wierenga, PhD to its board of directors.
Company Profile for Concert Pharmaceuticals, Inc.
Business Wire - Fri Mar 14, 9:40AM CDT
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform(R) (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.
Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors
Business Wire - Fri Mar 14, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today the appointment of Wendell Wierenga, Ph.D. to its board of directors. Dr. Wierenga is a seasoned executive with broad experience across all aspects of research, drug discovery and drug development including clinical research, regulatory affairs, manufacturing, safety, and medical affairs. Over the course of his career, he has been involved in over 70 INDs, 15 NDAs and 16 marketed products, including Lipitor(R), Neurontin(R), and Uceris(R).
Concert Pharmaceuticals Announces Exercise of Over-Allotment Option
Business Wire - Mon Mar 03, 10:30AM CST
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the underwriters for its initial public offering of common stock have exercised their over-allotment option and purchased an additional 649,690 shares. The additional shares were sold at the public offering price of $14.00 per share, before underwriting discounts. The closing occurred on March 3, 2014, bringing the total number of shares sold by Concert in the initial public offering to 6,649,690 shares, which represents a total capital raise of approximately $93 million before underwriting discounts.
Concert Pharmaceuticals to Present at the 26th Annual ROTH Conference on March 10, 2014
Business Wire - Mon Mar 03, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) will present a corporate overview at the 26th Annual ROTH Conference on Monday, March 10, 2014 at 9:00 a.m. PDT at the Ritz-Carlton Laguna Niguel, CA.
Concert Pharmaceuticals concludes IPO of 6m common shares
M2 - Thu Feb 20, 5:20AM CST
US-based biopharmaceutical company Concert Pharmaceuticals Inc (NasdaqGM:CNCE) revealed on Wednesday the completion of its initial public offering of 6m shares of its common stock.
Concert Pharmaceuticals Announces Closing of Initial Public Offering
Business Wire - Wed Feb 19, 10:30AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts.
Concert Pharmaceuticals Announces Pricing of Initial Public Offering
Business Wire - Thu Feb 13, 7:00AM CST
Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments. The shares are scheduled to begin trading on the NASDAQ Global Market on February 13, 2014 under the ticker symbol "CNCE."
Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer
Business Wire - Thu Jan 23, 6:00AM CST
Concert Pharmaceuticals, Inc. today announced the appointment of Ryan Daws as Chief Financial Officer. Mr. Daws brings to Concert more than 15 years of capital markets and financial advisory experience in the biotechnology and healthcare industry.
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59jtq3/chronic_kidney) has announced the addition of the "Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Concert Pharmaceuticals, Inc. - CorMedix, Inc. - Vitae Pharmaceuticals, Inc. - Stelic Institute & Co. - Sorbent Therapeutics, Inc. - Vicore Pharma AB - InVasc Therapeutics, Inc. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Chiasma, Inc. Drug Profiles - beraprost sodium LA - sotatercept - eculizumab - GCS-100 - deferiprone - (losartan potassium alpha lipoic acid) - tenapanor - LY-3016859 - enalapril maleate - SAR-407899 - VTP-27999 - CLP-1004 - CTP-499 - Ghrelin - THR-123 - C-21 - CAT-4000 Series - ANG-3070 - MultiGeneGraft - CXA-10 - CAT-4001 - SphK2 Program - TPX-200 - NZ-419 - Small Molecule to Inhibit Epoxide Hydrolase for Chronic Kidney Disease - Vida-5 - siRNA for Chronic Diseases - STNM-310 - ANG-4011 - Drug For Kidney Diseases - Chronic Kidney Disease Program - Drugs to Inhibit CYP24 for CKD and Pre-CKD - Small Molecules for Chronic Kidney Disease - Fluorophosphophloretin - BRN-1889 For more information visit http://www.researchandmarkets.com/research/59...nic_kidney
Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499 in Diabetic Kidney Disease
Business Wire - Fri Apr 25, 1:00PM CDT
--- CTP-499 reduced biomarkers of fibrosis -
Concert Pharmaceuticals, Inc. [CNCE] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Apr 11, 9:00AM CDT
What:
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.
Concert Pharmaceuticals Announces Filing of its Annual Report on Form 10-K
Business Wire - Mon Mar 31, 6:15AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.
Concert Pharmaceuticals Reports Year End 2013 Financial Results
Business Wire - Mon Mar 31, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.
Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting
Business Wire - Wed Mar 19, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that 48 week Phase 2 clinical results of CTP-499 in patients with diabetic kidney disease will be presented at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV. The podium presentation will be made by the lead author, Dr. Bhupinder Singh, a clinical investigator for the study at Southwest Clinical Research Institute, to present the clinical results during the Late Breaking Session on Friday, April 25, 2014, 9:30 am - 11:00 am PDT. A corresponding poster presentation will also be presented at the meeting and will include data describing the effect of CTP-499 treatment on several biomarkers of fibrosis. A copy of the corresponding abstract is available on the National Kidney Foundation's website at: http://www.kidney.org/news/meetings/clinical/.../index.cfm.
Concert Pharmaceuticals elects Dr Wendell Wierenga to board
M2 - Mon Mar 17, 5:05AM CDT
Biopharmaceutical company Concert Pharmaceuticals (NasdaqGM:CNCE) revealed on Friday the addition of Dr Wendell Wierenga, PhD to its board of directors.
Company Profile for Concert Pharmaceuticals, Inc.
Business Wire - Fri Mar 14, 9:40AM CDT
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform(R) (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.
Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors
Business Wire - Fri Mar 14, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today the appointment of Wendell Wierenga, Ph.D. to its board of directors. Dr. Wierenga is a seasoned executive with broad experience across all aspects of research, drug discovery and drug development including clinical research, regulatory affairs, manufacturing, safety, and medical affairs. Over the course of his career, he has been involved in over 70 INDs, 15 NDAs and 16 marketed products, including Lipitor(R), Neurontin(R), and Uceris(R).
Concert Pharmaceuticals Announces Exercise of Over-Allotment Option
Business Wire - Mon Mar 03, 10:30AM CST
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the underwriters for its initial public offering of common stock have exercised their over-allotment option and purchased an additional 649,690 shares. The additional shares were sold at the public offering price of $14.00 per share, before underwriting discounts. The closing occurred on March 3, 2014, bringing the total number of shares sold by Concert in the initial public offering to 6,649,690 shares, which represents a total capital raise of approximately $93 million before underwriting discounts.
Concert Pharmaceuticals to Present at the 26th Annual ROTH Conference on March 10, 2014
Business Wire - Mon Mar 03, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) will present a corporate overview at the 26th Annual ROTH Conference on Monday, March 10, 2014 at 9:00 a.m. PDT at the Ritz-Carlton Laguna Niguel, CA.
Concert Pharmaceuticals concludes IPO of 6m common shares
M2 - Thu Feb 20, 5:20AM CST
US-based biopharmaceutical company Concert Pharmaceuticals Inc (NasdaqGM:CNCE) revealed on Wednesday the completion of its initial public offering of 6m shares of its common stock.
Concert Pharmaceuticals Announces Closing of Initial Public Offering
Business Wire - Wed Feb 19, 10:30AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts.
Concert Pharmaceuticals Announces Pricing of Initial Public Offering
Business Wire - Thu Feb 13, 7:00AM CST
Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments. The shares are scheduled to begin trading on the NASDAQ Global Market on February 13, 2014 under the ticker symbol "CNCE."
Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer
Business Wire - Thu Jan 23, 6:00AM CST
Concert Pharmaceuticals, Inc. today announced the appointment of Ryan Daws as Chief Financial Officer. Mr. Daws brings to Concert more than 15 years of capital markets and financial advisory experience in the biotechnology and healthcare industry.
